Novartis forge deal with Boston Pharmaceuticals in effort against AMR
pharmafile | October 3, 2018 | News story | Research and Development | AMR, Antibiotics, Boston Pharmaceuticals, Novartis, US
Swiss multinational Novartis have entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates in an effort to boost Novartis’ Infectious Diseases portfolio. It is hoped that the deal may help tackle antibiotic resistant infections in the future.
“The need for new antibiotics that address drug resistant bacteria is clear and we are pleased to find a partner in Boston Pharmaceuticals who will dedicate the appropriate expertise and resources for the further development and commercialization of these programs,” said Dr Jay Bradner, President of the Novartis Institutes for BioMedical Research.
“Drug discovery and development is a team sport and this agreement is part of our strategy to partner with like -minded innovators outside of our walls to further develop new innovative medicines focused on addressing global health challenges.”
Under the terms of the agreement Novartis will receive an upfront payment while also being entitled to royalties. Novartis will also gain an equity share in the Cambridge, Massachusetts-based pharma firm.
“The acquisition of these three novel anti-infective candidates further demonstrates our commitment to addressing unmet medical needs in order to benefit patients,” said Robert Armstrong, Ph.D., C.E.O. of Boston Pharmaceuticals.
“Novartis has done a tremendous job advancing new solutions to infections caused by drug resistant Gram-negative pathogens and developing these innovative candidates with best-in-class or first-in-class potential. We look forward to building on this quality research as we advance these candidates.”
Louis Goss
Related Content
GSK pledges £45m to Fleming Initiative to fight AMR
GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first …
PeptiDream and Novartis extend peptide discovery collaboration
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
